CD274 and non-small cell lung carcinoma: For patients with PD-L1–positive NSCLC (≥ 50% expression) without other prognostic biomarkers, pembrolizumab and atezolizumab monotherapies, along with platinum-based IO combination therapy, are preferred 1L treatments in the current NCCN guidelines (version 6.2020).